Efficacy of Higher Albendazole & Ivermectin Doses on Wuchereria Bancrofti

Status Terminated

Clinical Trial Summary

Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major impediment to the success of programmes in many countries with limited financial resources.

Data from albendazole treatment of other filarial infections and one study comparing single to multi-dose Diethycarbamazine/albendazole in lymphatic filariasis suggest that increased dose and/or frequency of albendazole dosing may be more effective in clearing microfilariae. It is essential to determine whether such higher doses are indeed beneficial since this could have far-reaching effects on the conduct and management of the main mass treatment programmes and also in the management of programmes as they near elimination.

Clinical Trial Description

The proposed study will enrol up to 120 volunteers with microfilaremic Wuchereria bancrofti infection who would be randomized to receive standard annual treatment (albendazole 400 mg + ivermectin 200 mcg/kg), annual treatment with an increased dose of albendazole (albendazole 800 mg + ivermectin 200400 mcg/kg) or semi-annual treatment with a standard (albendazole 400 mg + ivermectin 200 mcg/kg), or an increased albendazole dose (albendazole 800 mg + ivermectin 200 400 mcg/kg). Microfilarial levels, as well as measures of adult worm burden (circulating antigen) will be followed every six months for two years to determine whether the higher doses, or more frequent regimens are more effective.

The data obtained would be used, in combination with the data from other similar studies being conducted in Mali and in India to advise the Global Programme for the Elimination of Lymphatic Filariasis (GPELF) on improved methods of treatment both for mass treatment and for the management of problem areas within the global programme. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01213576
Study type	Interventional
Source	London School of Hygiene and Tropical Medicine
Contact
Status	Terminated
Phase	N/A
Start date	January 2009
Completion date	February 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00375583` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Completed	`NCT03664063` - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )	Phase 2
Recruiting	`NCT04844905` - Adjunctive Ivermectin Mass Drug Administration for Malaria Control	Phase 3
Completed	`NCT01975441` - Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa	Phase 2
Completed	`NCT01629771` - Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India	N/A
Completed	`NCT01905423` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Completed	`NCT02784743` - Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali	Phase 4
Completed	`NCT03036059` - Twice Yearly Treatment for the Control of LF	Phase 4
Completed	`NCT01905436` - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed	`NCT02509481` - Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study	Phase 2/Phase 3
Completed	`NCT03268252` - Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Completed	`NCT02927496` - A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali	Phase 3
Completed	`NCT02899936` - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis	N/A
Completed	`NCT00511004` - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis	Phase 2
Active, not recruiting	`NCT04258670` - Spontaneous Antigenemia in Loiasis
Completed	`NCT02974049` - Lymphatic Filariasis (LF) in Ivory Coast	N/A
Completed	`NCT02929121` - A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India	Phase 3
Completed	`NCT00339417` - Effect of Albendazole Dose on Clearance of Filarial Worms	Phase 2
Completed	`NCT02032043` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Withdrawn	`NCT01903057` - Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi — FED

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms